Apollomics Inc. income statement APLMW

Annual Quarterly

In fiscal 2024, which ended Dec 31, 2024, Apollomics Inc. reported revenue of $0. It recorded a net loss of $53.9 million. Diluted earnings per share were -$52.80.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Revenue
0
0
0
Research and development
25
-28.2%
34
-3.6%
35
Operating income
—
—
1
Pretax income
-54
+68.9%
-173
+28.3%
-241
Income tax
0
+2490.0%
0
+900.0%
0
Net income
-54
+68.8%
-173
+28.3%
-241
Basic EPS
-52.80
+77.2%
-231.99
+72.5%
-844.95
Diluted EPS
-52.80
+77.2%
-231.99
+72.5%
-844.95
Weighted average shares, basic
1
+37.1%
1
+161.1%
0
Weighted average shares, diluted
1
+37.1%
1
+161.1%
0
Other measures
Interest coverage
—
—
10.49x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
APLM (Nasdaq), APLMW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Covina, CA
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1944885

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.